U.S. access group aims to block Indian patent for Gilead’s hot hep C drug

Tracy Staton

Gilead Sciences' new hepatitis C sofosbuvir won preliminary backing from European regulators on Friday, with marketing approval expected to follow soon. The FDA is expected to clear the for take-off Dec. 8, if not sooner. All good for the California-based drugmaker. But there's a battle over sofosbuvir brewing in India.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS